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Abstract
Background: The economic benefits of healthcare research require study so that appropriate resources can be
allocated to this research, particularly in developing countries. As a first step, we performed a systematic review to
identify the methods used to assess the economic impact of healthcare research, and the outcomes.
Method: An electronic search was conducted in relevant databases using a combination of specific keywords. In
addition, 21 relevant Web sites were identified.
Results: The initial search yielded 8,416 articles. After studying titles, abstracts, and full texts, 18 articles were
included in the analysis. Eleven other reports were found on Web sites. We found that the outcomes assessed as
healthcare research payback included direct cost-savings, cost reductions in healthcare delivery systems, benefits
from commercial advancement, and outcomes associated with improved health status. Two methods were used to
study healthcare research payback: macro-economic studies, which examine the relationship between research
studies and economic outcome at the aggregated level, and case studies, which examine specific research projects
to assess economic impact.
Conclusions: Our study shows that different methods and outcomes can be used to assess the economic impacts
of healthcare research. There is no unique methodological approach for the economic evaluation of such research.
In our systematic search we found no research that had evaluated the economic return of research in low and
middle income countries. We therefore recommend a consensus on practical guidelines at international level on
the basis of more comprehensive methodologies (such as Canadian Academic of Health Science and payback
frameworks) in order to build capacity, arrange for necessary informative infrastructures and promote necessary
skills for economic evaluation studies.
Background
Healthcare research can expand the frontiers of science,
save human lives, and improve quality-of-life. One of
the most fundamental challenges is the appropriate allo-
cation of public and private funds to this research sec-
tor. The 2008 ‘Global Ministerial Forum on Research
for Health’ in Mali hosted ministers and representative
councils from 59 countries. This forum concluded that
each country should allocate 2% of Health Ministry
funds to healthcare research [1]. Despite agreement that
there is a need to increase funding for healthcare
research, it remains difficult to convince governments
and the private sector to invest in such research,
especially in developing countries, which have limited
financial resources. In recent years, investors and
researchers have focused on the presumed benefits of
healthcare research projects, so it is now necessary for
health research systems to consider costs and benefits.
A reduction in healthcare research funding is likely
given the current economic crisis, particularly in coun-
tries that have previously been unable to allocate suffi-
cient funds for this purpose. In fact, before many
countries can attain suitable public health standards,
they will be faced with reductions in research funds,
making it even more difficult to attain the required stan-
dards. The WHO ‘Financial Crisis and Global Health’
report emphasizes that healthcare research is not a lux-
ury, but is rather vital for meeting the needs of the
healthcare sector in times of economic crisis [2]. There-
fore, we suggest that every country should evaluate the
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cient funds for this endeavor. The current study was
designed to identify available methods of measuring the
economic impact of healthcare research.
Methods
An electronic search of English-language articles was
conducted in numerous bibliographic databases in
March of 2009 using a combination of keywords: health
research, health system research, medical research, pay-
back, impact, assessment, evaluation, research utiliza-
tion, rate of return, internal rate of return and net
present value. The databases searched were PubMed,
CINAHL, Dissertation and Thesis, Urban History, Leice-
ster, Australian Digital Thesis Program, DART-Europe
E-theses Portal, and the University of Michigan’sO A l -
ster service.
An electronic search was also performed to locate 21
relevant websites (Table 1). Reports that were relevant
to our study were chosen from these websites. The
entire article-screening procedure was conducted inde-
pendently by two individuals. Where disagreement was
evident, a final decision was achieved by discussion and
consultation.
Results
We identified 8,416 articles in our electronic search. In
primary screening that considered title and abstract (if
there was an abstract), we identified 208 potentially rele-
vant articles and subsequently requested the full texts, of
which 196 were accessible. The secondary screening,
which examined the full texts, yielded 18 relevant arti-
cles. We identified 11 other reports by searching Web
sites (Table 1).
Some of these studies introduced theoretical defini-
tions and frameworks, and others used practical mea-
surements of the economic impact of healthcare
research. A review of included studies indicated that
evaluations of the economic impact of healthcare
research were performed (a) to estimate the economic
benefits of projects as a criterion for prioritizing
research [3-8], and, (b) to determine the investment
returns of projects (Table 2). Our study focuses on the
investment returns of healthcare research projects.
After reviewing the studies, we found that different
methods and criteria were used to study the economic
impacts of healthcare research. To measure the eco-
nomic benefits of healthcare research, four questions
must be answered:
Table 1 Sites studied
Site Address
Canadian Institute of Health Research http://www.cihr-irsc.gc.ca/e/193.html
Research Unit for Research Utilization http://www.ruru.ac.uk/index.html
Organization for Economic Cooperation and Development http://www.oecd.org/about/0,3347, en_2649_34409_1_1_1_1_1,00.html
Canadian Health Services Research Foundation http://28784.vws.magma.ca/about/index_e.php
Industry Canada http://www.ic.gc.ca/cgi-bin/sc_mrksv/bnkrptcy/ud/ud_srch.pl?lang=eng
ResearchResearch.com http://www.researchresearch.com/getPage.cfm
Health Economic Research Group (HERG) http://www.brunel.ac.uk/about/acad/herg/aboutherg
Research America http://www.researchamerica.org/about
University of Houston System http://www.advancement.uh.edu/impact/index.html
McCaughey Center http://www.mccaugheycentre.unimelb.edu.au/
Academy Health http://www.academyhealth.org/about/index.htm
English Wikipedia http://en.wikipedia.org/wiki/Health_Impact_Assessment#Overview
Pacific Research Institute http://liberty.pacificresearch.org/default.asp
UNC School of Public Health http://www.sph.unc.edu/
IMS Health http://www.imshealth.com/web/channel/0,3147,77141581_63872702_79014008,0_
0.html
Yale University http://info.med.yale.edu/womenshealth//about/index.html
University of Texas http://www.utexas.edu/
Banner Health http://www.shri.org/index.cfm
Health Research Council of New Zealand http://www.hrc.govt.nz/index.html
Rural Health Research Gateway http://www.ruralhealthresearch.org/
Primary Health Care Research and Information Service (PHC RIS) http://www.phcris.org.au/index.php
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nomic impacts of research?
2. What economic outcomes can be attributed to
research?
3. How can healthcare status be described by finan-
cial indicators?
4. When should we evaluate the economic benefits
of research?
What methods can assess the economic impacts
of research?
Two methods can be used to assess the economic
impacts of healthcare research; these are macroeco-
nomics and case studies. Macroeconomic studies exam-
ine the relationship between the costs of conducting
research and benefits gained at macro level and calcu-
late the overall return but do not specify the process (in
epidemiological studies; an ‘ecologic study’ is identical
to a ‘macroeconomic study’). Examples of such studies
are the exceptional return reports prepared in America
in 2000 [9], similar studies in Australia in 2003 and
2005 [10,11] and the study of “Medical Research: What’s
it worth? Estimating the economic benefits from medical
research in the UK in 2008”[12].
The American report considered mortality and
increased life expectancy as outcomes of research [9].
The Australian studies reviewed nationwide mortality
and morbidity and the association between research
investment and economic benefits. The main limitation
of such studies is the presence of multiple confounding
factors and the attribution problem.
In addition to showing the overall return rate, the UK
study ‘Medical Research - What’si tw o r t h ?i sa ne x a m -
ple of a study that calculates factors such as lag time,
Table 2 Selection of studies reviewed in this study
For priority setting before doing the
project
Karnon J, Planning the efficient allocation of research funds: an adapted application of a non-
parametric Bayesian value of information analysis,2002 [3]
Townsend J, Prioritisation of health technology assessment. The PATHS model: methods and case
studies,2003 [8]
Coyle D, The assessment of the economic return from controlled clinical trials. A framework applied
to clinical trials of colorectal cancer follow-up,2003 [5]
Fleurence RL, Setting priorities for research,2004 [6]
Claxton KP, Using value of information analysis to prioritise health research: some lessons from recent
UK experience, 2006 [4]
Fleurence RL, Setting priorities for research: a practical application of ‘payback’ and expected value of
information,2007 [7]
For estimation of the economic impact
after doing the project
Macroeconomic studies Exceptional Returns: The Economic Value of America’s Investment in Medical Research.2000 [9]
Exceptional Returns the Value of Investing in Health R&D in Australia,2003 [10]
Exceptional Returns: The Value of Investing in Health R&D in Australia II,2005 [11]
Medical Research: What’s it worth? Estimating the economic benefits from medical research in the
UK. Evaluation Forum,2008[12]
Case studies Hanney S, Proposed methods for reviewing the outcomes of health research: the impact of funding
by the UK’s ‘Arthritis Research Campaign’,2004 [15]
Wooding S, Payback arising from research funding: evaluation of the Arthritis Research
Campaign,2005 [16]
Kwan P, A systematic evaluation of payback of publicly funded health and health services research in
Hong Kong,2007 [18]
Wooding S, Policy and practice impacts of research funded by the Economic and Social Research
Council, A case study of the Future of Workprogramme, approach and analysis,2007 [20]
Nason E, Health Research- Making an Impact, The Economic and Social Benefits of HRB Funded
Research,2008 [17]
Kalucy L, Exploring the impact of primary health care research. Primary Health Care Research and
Information Service, 2009 [19]
Introducing the framework Buxton M, How can payback from health research be assessed, 1996 [13]
Canadian Institutes of Health Research, Developing a CIHR Framework to Measure The Impact of
Health Research,2005 [21]
Kuruvilla S, Describing the impact of health research: a Research Impact Framework [23]
Canadian Academy of Health Sciences, Making an Impact, A Preferred Framework and Indicators to
Measure Returns on Investment in Health Research,2009 [22]
Theoretic discussion about economic
impact
Croxson, B, Routine monitoring of performance: what makes health research and development
different, 2001 [32]
Peipert, J.F, The economic value of medical research: is it worth the investment, 2002 [33]
Sajal K. Chattopadhyay, Economics of Prevention: The Public Health Research Agenda, 2004 [34]
Michele S. Garfinkel, A Societal Outcomes Map for Health Research and Policy,2006 [35]
Anthony P. Weiss, Measuring the Impact of Medical Research:Moving From Outputs to Outcomes,
2007 [36]
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treatments [12].
Case studies examine the impact of specific healthcare
research, investigate the details of return and propose
ideas for increasing it. To evaluate healthcare research
in case studies, researchers have defined frameworks
that classify the impact of healthcare research in various
dimensions, one of which is economic impact. The fra-
meworks identified in this study and the economic out-
comes proposed are as follows:
The Payback framework
This framework was introduced by the “Health Econom-
ics Research Group” (HERG) of Brunel University in the
UK in 1996, and was completed over several years
[13-16]. One aspect of the framework was ‘Broader eco-
nomic benefits’. In this area, the authors defined broader
economic benefits as “benefits resulting from commer-
cial utilization of research innovations”,a n d“benefits
resulting from healthy workforce and reduction of days
off work”. This framework was examined in seven stu-
dies performed in the United Kingdom, Ireland, The
Netherlands, and Hong Kong that were slightly modified
according to local conditions and requirements [17-20].
Some studies considered ‘worker stress reduction’, ‘pub-
lic health promotion’, ‘mental health promotion’, ‘reduc-
tion of the unemployed’, ‘higher productions’,a n d
‘increasing equity’ as economic benefits. Another study
considered the following asp e c t sa se c o n o m i cb e n e f i t s :
recruiting and keeping high-quality researchers, estab-
lishing or re-activating new companies, employing peo-
ple in laboratories, increasing international funds,
attracting external investment, continuing to invest in
foreign companies, attracting funds for future research,
introducing the country as a center-of-excellence, inter-
national recognition, facilitating access to current and
available scientific recognition, identification of groups
at risk for intervention, and research advancements in
healthcare delivery systems and planning.
Interestingly, some of these factors carry meaningful
economic benefits only at national level, and cannot be
considered of significance on an international scale. All
cited studies indicated the appropriateness and practical-
ity of using the payback framework.
This approach has also been used in the design of the
‘Canadian Institutes of Health Research’ [21] and the
‘Canadian Academy of Health Science’ frameworks [22].
This illustrates that the payback framework can cover
all aspects of healthcare research.
Canadian Institutes of Health Research framework [21]
This version of the payback framework was introduced by
the ‘Canadian Institutes of Health Research’ in 2005. Here,
the economic impacts of healthcare research are classified
into four domains: commercial benefits, direct cost-sav-
ings, human capital, and the value of life and health.
The framework also describes how these domains are
measured. In the commercial benefits domain, the
major indicators are number and types of patents, spin-
off companies and licenses for intellectual property gen-
erated, and financial returns from intellectual rights. In
the direct cost-savings domain, Estimating the economic
value of innovations created by health research, and (in
the human capital domain), calculation of the reduction
in production losses resulting from illness and/or injury,
are the major indicators. In the value of life and health
domain, the main indicator is the economic value of the
extra years of life gained through novel treatments.
Research impact framework [23]
This framework was introduced in 2006. Here, also,
multiple dimensions have been described for assessing
the impact of research, two of which account for eco-
nomic benefits. These are ‘service impact’ and ‘societal
impact’. ‘Service impact’ refers to cost savings in health-
care delivery systems (’limitation and effectiveness of
costs’). The ‘societal impact’ refers to economic benefits
at the macro level, such as the commercial benefits of
producing and selling products, selling more effective
procedures to industry, transfer of healthcare programs
to the private sector, and the benefits of healthy work-
places and healthy lifestyles (’macro-economic impacts’).
Canadian Academy of Health Sciences [22]
This framework was introduced in 2009, and has five
domains that describe the impact of healthcare research.
One advantage of this framework is that in addition to
describing the indicators, applications are also proposed.
The economic and social impacts of this framework
include the following indicators:
1. Activity impact indicators:
Labor rent or economic rent: economic impacts (with
m o n e t a r yc r i t e r i a )t h a tr e s u l tf r o me m p l o y m e n ti n
healthcare research rather than other sectors.
2. Commercial indicators:
◦ Licensing returns: money spent in obtaining
licenses and/or certificates, considering the associa-
tion between these materials and specific research.
◦ Product sales revenues: benefits of product sales,
which are dependent on multiple factors.
◦ Valuation of spin-out companies: portfolio values of
spin-out companies and sales of such companies.
◦ Economic rent (producer rent and spillover effects):
‘Producer rent’ is the economic benefit to a company
when expected revenues are exceeded. The ‘spillover
effect’ is the impact of investment in research and devel-
opment on groups that did not receive direct funding.
3. Health benefit indicators: the value of results in
terms of healthcare benefits, as measured by the Quality
Adjusted Life Years (QALYs) scale.
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non-isolation of individuals, and several other indicators.
5. Social benefit indicators: extent of changes in socio-
economic because of healthcare research.
Table 3 presents a summary of the economic indica-
tors defined in the various frameworks.
What economic outcomes are attributable to research?
Healthcare research can benefit both human health and
the economy, and the improvement in human health
can be described by economic indicators. Multiple defi-
nitions and classifications have been proposed to explain
the direct economic benefits of healthcare research, such
as direct cost-savings resulting from research-driven
innovation, cost-savings in service delivery systems, and
benefits from commercial development of products and
technologies [10,17,24]. Criteria such as death reduction,
increase in lifespan, reduction of diseases, and increase
in quality-of-life and life expectancy are used to assess
health status. In the UK study ‘Medical Research -
What’si tw o r t h ? ’ the QALYs gained and impact on the
GDP of the UK (the ‘spillover effect’) that resulted from
cardiovascular and mental health research were consid-
ered as outcomes in study of the economic impact of
medical research [12].
Different methods have been proposed to identify the
impact of healthcare research on human health for the
purpose of differentiating it from other factors. One
proposal is the study of short-term effects of specific
efforts, such as cardiovascular research. Such research
can include diagnostic and therapeutic studies on tar-
geted patient populations, or preventative research on
nutrition and lifestyle in apparently healthy targeted
populations. The time horizon and target population
should be considered in addressing the attribution pro-
blem. Thus, ‘reduced mortality after myocardial infarc-
tion’ may be used as an outcome of diagnostic and
therapeutic research, and ‘overall reduction of cardiovas-
cular disease mortality’ over an extended period of time
may be used in preventative studies. The latter criterion
may be influenced by behavioral changes and improved
lifestyle, which lead to disease reduction, but not neces-
sarily to reduced mortality [25].
An attribution of 50% is considered acceptable in some
studies, and a sensitivity analysis of 30-70% has been
used to reflect the uncertainty in the estimate [11]. How-
ever, one study showed that, with cardiovascular disease,
one-third of the reduced mortality was attributable to
aggressive treatments, one-third to pharmacologic devel-
opments, and one-third to behavioral changes [26]. Thus,
when measuring the return of pharmacologic research on
cardiovascular disease, it could be considered that only
one-third of mortality and morbidity reduction may be
attributed to pharmacologic developments.
How can healthcare status be described by
financial indicators?
Once the health status outcome is determined, it is
necessary to describe this by use of financial indicators.
Methods such as ‘individual willingness-to-pay’,a‘pro-
ductivity approach’ (e.g. additional earnings of cancer
survivors [11,27], and ‘maximum funds provided by the
health delivery system to obtain one health unit’ [17]
have been used.
When should we evaluate the economic benefits
of research?
There is no general consensus on the timeframe needed
to assess the economic benefits of healthcare research,
but some researchers have proposed 3-5 years as appro-
priate [21]. After examining various studies, the ‘Medical
Research - What’s it worth?’ study in 2008 suggested 10-
25 years (average: 17 years) for cardiovascular research
and 9-14 years (average: 12 years) for mental health
research as the average time from research to health
impact [12]. However, the duration will depend on the
type of study, the expected impact and the particular
circumstances of each individual country.
Discussion
Various methods and approaches are used for the eco-
nomic assessment of healthcare research. There are two
basic methods for studying such benefits: macroeco-
nomic evaluation of the relationship between funds
spent on research and economic benefits, and case stu-
dies which examine a single research or program.
It is often difficult to attribute an observed change in
public health as causally related to funding for healthcare
Table 3 Indicators defined for measuring economic
benefits of health research in available frameworks
Framework Economic Benefits
Payback [13-16] ￿ benefits resulting from commercial
utilization of research innovations
￿ benefits resulting from healthy
workforce and reduction of days off
work
Canadian Institute of Health ￿ commercial benefits
Research framework [21] ￿ human investments
￿ the value of life and health
Research impact [23] ￿ limitation and effectiveness of
costs
￿ macro-economic impacts
Canadian Academic of Health ￿ Research activity benefits
Science Framework [22] ￿ Commercial benefits
￿ Health benefits
￿ Well-being benefits
￿ Social benefits
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one of the rationales for case studies and for employing
specific frameworks that facilitate the evaluation process.
Among the available frameworks, the payback framework
[13] has been used as a basis for all other frameworks,
and has been employed more than any other model. The
Canadian Academy of Health Science (CAHS) framework
[22] is one novel proposed approach, the suitability and
practicality of which have not yet been examined,
although it does provide a more complete and compre-
hensive overview of the economic impact of healthcare
r e s e a r c h .I tm u s tb ek e p ti nm i n dt h a te a c ho ft h ea v a i l -
able frameworks was designed for specific reasons.
A review of all relevant studies indicates that attribu-
tion of economic benefits to healthcare research requires
that the impacts of interventions are measured. In fact,
in such studies, research results should be attributed to
a decision or change in behavior of a target group, and,
next, the impact of the decision or behavioral change
should be measured. Therefore, consideration of the
implementation of results is very important in assessing
the benefits of healthcare research [28].
Another important consideration is the cost of imple-
menting interventions. For evaluation of the economic
impact of healthcare research, two types of costs must be
considered: the cost of conducting research, and the cost
of implementing research results. Regarding the cost of
research, combined indicators can be used to describe
costs and benefit. Thus, combined indicators such as ‘net
present value’, ‘return on investment’,a n d‘benefit-cost
ratio’ can be used [11]. For healthcare research to provide
economic benefits, results must be implemented, but it is
unclear whether the costs of implementing such results
should be considered in evaluating the final economic
benefits. Some researchers believe that the expense of
implementing research results should be considered in
evaluation of the economic benefits of such research
because high expense is of little benefit for patients who
are near death; research on novel care techniques has
fewer benefits than research on preventative methods;
and theoretical estimates have shown that, for specific
gender and age groups, the benefits of prolonging life are
less than curative expenditures [25]. The authors believe
that it is only logical and necessary to take into account
the cost of implementation of research in valuing health-
care research whose ultimate goal is to improve commu-
nity’s health.
In the studied reports, the sections on evaluation of
the economic impacts of healthcare research are often
the weakest, perhaps because of the absence of appro-
priate data. In fact, in most studies the researchers sim-
ply forecast economic impact, and do not actually
measure outcomes. In some cases, data from other
related or unrelated healthcare sectors can be used, but
this information is not always available or complete.
Thus, separate studies are needed to evaluate the eco-
nomic benefits of healthcare research. Also, to facilitate
the evaluation of the economic impacts of such
research, the criteria used to define benefits and the
sources of necessary information should be clearly iden-
tified from the beginning.
The indicators used to assess the economic impacts of
healthcare research depend on the type of study. Thus,
research projects can be classified as etiologic, interven-
tional, policy analysis, health service, theoretical, metho-
dological or healthcare system studies [29]. Based on the
type of study, the expected economic impact, the time
required to assess the impact, and comprehensive and
practical indicators, should be clearly defined and speci-
fied. To facilitate economic evaluation, we suggest that
researchers add sections to their reports in which the
expected economic impacts are explicitly stated.
Another important issue is consideration of the bene-
fits from domestic and foreign investment in healthcare
research. Some interventions, technologies, and drugs
used in a country actually result from research con-
ducted in other countries, so not all economic benefits
can be classified as domestic. The ‘Medical Research -
What’si tw o r t h ? ’ study has used citations to relevant
clinical guidelines to calculate the attribution of devel-
opments made in cardiovascular and mental health
research in the UK to medical research worldwide [12].
The potential benefits of local investment in the
research results of other countries should not be over-
looked. Studies conducted to implement the research
results from overseas (effectiveness studies), or invest-
ment in developing a drug that is produced in another
country, can both be considered as investment in local
research (the ‘spillover effect’).
Care must be taken in interpreting economic evalua-
tion studies on health research. Be it positive or nega-
tive, these results may be the effect of various
methodology flaws that over-represent or under-repre-
sent the true effects of research, and should be taken
into account while interpreting their results. The eco-
nomic benefits of healthcare research may be assessed
incorrectly in the following cases: absence of valid, reli-
able and operational indicators for measuring economic
benefits; use of incorrect and incomplete data. Even if it
is proven that the investment return is low or negligible,
it is still necessary to assess economic benefits, because
this can indicate a waste of resources and the weak-
nesses should be identified using the assessment results
and consequently be corrected.
Conclusions
Healthcare research strategies have undergone signifi-
cant changes over the past 20 years. Previously, ‘capacity
Yazdizadeh et al. Health Research Policy and Systems 2010, 8:6
http://www.health-policy-systems.com/content/8/1/6
Page 6 of 8building’ was a significant focus, and this led to health-
care research methodology workshops, especially in the
1980s. Next, identification of the ‘10/90 gap’ (10% of
worldwide expenditure on healthcare research is devoted
to problems that primarily affect the poorest 90% of the
population) led to re-prioritization of research focus[30].
Since then, the gap between research and the effects on
human health have been identified, and knowledge
translation was considered one of the main strategies of
healthcare research in 2004, as emphasized in the
Bamako Forum of 2008 [31]. Now that the world has
entered an economic crisis, we suggest that it is impor-
tant that the economic outcomes of research should
play a pivotal role in healthcare research.
We found no reports on the research payback of low
and middle income countries who have less financial
resources (and allocate a smaller share of their GDP to
health and its relevant researches) in our systematic
review. This may partly be due to publication bias, but
lack of the necessary infrastructure and skills for per-
forming research payback studies in such countries is
no doubt another reason. We suggest that international
organizations, such as the World Health Organization
and ‘The Alliance for Health Policy and Systems
Research’ or other global initiatives seek to propagate,
facilitate, and compare healthcare research economic
evaluation throughout the world. Frameworks that have
introduced more appropriate components (such as
CAHS and payback frameworks) can be considered as
the basis in this respect, and practical guidelines for
capacity building and arranging necessary informative
infrastructures should be introduced to better protect
health research in these countries.
This movement should be launched with the aim of
‘compiling a standard methodology on the basis of
objectives, information, and available facilities in devel-
oped and developing countries’, ‘preparation and disse-
mination of tools required for measuring economic
outcomes of health research’,a n d‘specification of the
expected economic outcomes’.T h i sw i l lh e l pu st o
achieve the goals agreed upon at the Bamako Global
Ministerial Forum on Research for Health in 2008.
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